EGFL7 augments MM growth in vivo. (A) Human RPMI8226 wild-type cells were injected s.c. into NOD/SCID mice (n = 6/group). (B) Human EGFL7 plasma levels were measured in murine plasma samples at indicated times by enzyme-linked immunosorbent assay in (n = 6). (C) Representative western blotting for EGFL7 and b-ACTIN in tumors extracted from tumors injected with Mock, EGFL7 OE, or KD RPMI8226 cells. (D-E) The size of tumors that formed after s.c. injection of Mock, EGFL7 OE, or KD cells after day 53. (D) Tumor weight was measured (left panel; n = 6/group). Representative macroscopic tumor images were taken on day 53 postinoculation (right panel). (E) Representative hematoxylin and eosin-stained tumor sections demonstrating increased necrotic areas (yellow lines) in tumors established with EGFL7 KD cells (scale bar, 200 µm). (F-G) RPMI8226 wild-type tumor-bearing NOD/SCID mice were injected with/without neutralizing Abs against EGFL7 (anti-EGFL7) starting after visible tumors had been established by day 25 (n = 6/group). (F) Tumor weight on day 53 after initial tumor inoculation (left panel). Representative macroscopic images of tumors (right panels). (G) Histological images of hematoxylin and eosin–stained tumor sections (scale bar of the insert, 100 µm). Graphs show mean ± SEM. Significance was calculated by Student t test, * P ≤ .05; ** P ≤ .01.